Latest Content

  • Post-EASL Update: What Is the Role of Treatment Guidelines in the Current HCV Era?

    Jordan J. Feld MD, MPH - 5/22/2014 8 comments / Last Comment: 8/26/2014
    With the new era of HCV therapies comes a new era in clinical guidelines; although there is certainly overlap, the major guidelines serve different but important roles.
  • Post-EASL Update: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed

    Stefan Zeuzem MD - 5/19/2014 7 comments / Last Comment: 8/31/2014
    Following new data from the ION-2 study reported at EASL 2014, options for retreatment of patients with previous PI failure appear much improved.
  • Post-EASL Update: Reconsidering Whether to Treat Genotype 1 HCV Patients or Wait for All-Oral Therapy

    Paul Y. Kwo MD - 5/12/2014 4 comments / Last Comment: 8/23/2014
    Following the presentation of phase III data on new all-oral regimens for genotype 1 HCV at EASL, which patients might wait for the approval of new therapies and which should be treated now?